Request to Watch Our Webinar On Demand
Drug discovery is the foundation of the pharma and biotech effort to search for novel therapeutics that are safe and treat life-altering diseases. Pharma companies are continuously challenged to become more innovative, efficient, and productive in their hunt for new efficacious drugs. Coupled with the increased complexity of therapeutic approaches and pressures to externalize portions of their discovery, this has led to a change in the type of partnership a pharma company needs when they search for a contract research organization (CRO) partner.
In this webinar, we illustrate data and expertise-driven enhancement of inflammatory bowel disease (IBD) models with proteomic characterization of both human ulcerative colitis and two murine IBD models. Proteomic profiling identifies disease features that correlate with histology-based disease severity metrics and further distinguishes target and pathway differences that can provide a basis for matching a model to a therapeutic.
Innovation Strategy for BioPharma: Proteomics for Optimal Selection of Preclinical Efficacy Models
Presented by Matt Hutzler, Executive Director, Scientific Engagement, and Daniel Liebler, Vice President, Translational Platforms
Complete the form to watch this webinar and learn how we can become your trusted partner.
